Reality Check on Soft Tissue Sarcoma
Market access for soft tissue sarcoma treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.
To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:
- Payer Insights: Under the pharmacy benefit, about 60% and 70% of the lives under commercial and Medicare formularies are covered with utilization management restrictions, respectively
- Class Trends: In April 2019, Eli Lilly and Co. said it will withdraw advanced soft tissue sarcoma drug Lartruvo (olaratumab) from the market. The move follows the failure of a Phase III trial in which the therapy did not improve patient survival
- Key Findings: Most products in this class have written policies from payers. In general, more policies exist for the oral agents than the intravenous, physician-administered products
What can pharma do to curb this trend and overcome these challenges?
Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.
Download the full Reality Check now.